BCL2L1 and cancer: In these cancer cells, the decoy LODN should induce cell killing predominantly through inhibition of NF-kappaB-induced MGMT expression, but also it might exert its effect through inhibition of other NF-kappa B-regulated genes such as anti-apoptotic (IAP1, IAP2, XIAP Bcl-2, Bcl-xL, and survivin) [48], [49] and proliferative genes (cyclin D1, cyclooxygenase-2, and c-Myc) [50]–[52].